Rapport PROMs 'Inventarisatie en realisatie patiëntgerapporteerde uitkomsten 13 aandoeningen'
Lees nu het rapport met aanbevelingen over PROMs voor 13 chirurgische aandoeningenBekijk artikel
Leonie van der Werf, arts-onderzoeker bij DICA, en collega's hebben een onderzoek met data uit de Dutch Upper GI Cancer Audit (DUCA) gepubliceerd in het European Journal of Cancer:
Time interval between neoadjuvant chemoradiotherapy and surgery for oesophageal or junctional cancer: A nationwide study.
Auteurs: Auteurs: L.R. van der Werf, J.L. Dikken, E.M. van der Willik, M.I. van Berge Henegouwen, G.A.P. Nieuwenhuijzen, B.P.L. Wijnhoven, On behalf of the Dutch Upper Gastrointestinal Cancer Audit (DUCA) group
Lees het hele artikel in het European Journal of Cancer; hieronder staat een samenvatting van het artikel.
The optimal time between end of neoadjuvant chemoradiotherapy (nCRT) and oesophagectomy is unknown. The aim of this study was to assess the association between this interval and pathologic complete response rate (pCR), morbidity and 30-day/in-hospital mortality.
Patients with oesophageal cancer treated with nCRT and surgery between 2011 and 2016 were selected from a national database: the Dutch Upper Gastrointestinal Cancer Audit (DUCA). The interval between end of nCRT and surgery was divided into six periods: 0-5 weeks (n = 157;A), 6-7 weeks (n = 878;B), 8-9 weeks (n = 972;C), 10-12 weeks (n = 720;D), 13-14 weeks (n = 195;E) and 15 or more weeks (n = 180;F). The association between these interval groups and outcomes was investigated using univariable and multivariable analysis with group C (8-9 weeks) as reference.
In total, 3102 patients were included. The pCR rate for the groups A to F was 31%, 28%, 26%, 31%, 40% and 37%, respectively. A longer interval was associated with a higher probability of pCR (≥10 weeks for adenocarcinoma: odds ratio [95% confidence interval]: 1.35 [1.00-1.83], 1.95 [1.24-3.07], 1.64 [0.99-2.71] and ≥13 weeks for squamous cell carcinoma: 2.86 [1.23-6.65], 2.67 [1.29-5.55]. Patients operated ≥10 weeks after nCRT had the same probability for intraoperative/postoperative complications. Patients from groups D and F had a higher 30-day/in-hospital mortality (1.80 [1.08-3.00], 3.19 [1.66-6.14]).
An interval of ≥10 weeks for adenocarcinoma and ≥13 weeks for squamous cell carcinoma between nCRT and oesophagectomy was associated with a higher probability of having a pCR. Longer intervals were not associated with intraoperative/postoperative complications. The 30-day/in-hospital mortality was higher in patients with extended intervals (10-12 and ≥15 weeks); however, this might have been due to residual confounding.